Trials / Completed
CompletedNCT01859988
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 380 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of multiple dupilumab dose-regimens, compared to placebo, in adult participants with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dupilumab | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-05-01
- Completion
- 2014-09-01
- First posted
- 2013-05-22
- Last updated
- 2017-08-28
- Results posted
- 2017-08-28
Locations
84 sites across 7 countries: United States, Canada, Czechia, Germany, Hungary, Japan, Poland
Source: ClinicalTrials.gov record NCT01859988. Inclusion in this directory is not an endorsement.